ARID1A IHC is a reliable tool to identify these aggressive tumors. Associated PD-L1 expression may offer new therapeutic options via checkpoint inhibitors.

3 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • ARID1A (AT-rich interaction domain 1A)

PD-L1 expression • ARID1A mutation • PD-L1 negative

Clinicogenomic Landscape of Histologic Subtypes in Ovarian Cancer: Real-World Evidence From a Japanese Nationwide Cohort. (PubMed, JCO Precis Oncol)

This large clinicogenomic study in an Asian population highlights unique mutational landscapes and survival associations, which may inform personalized treatment strategies.

7 days ago

Retrospective data • Journal • HEOR • Real-world evidence • BRCA Biomarker

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • KEAP1 (Kelch Like ECH Associated Protein 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)

TP53 mutation • KRAS mutation • BRCA2 mutation • PIK3CA mutation • ARID1A mutation • CDKN2A deletion • KEAP1 mutation • NFE2L2 mutation

Deciphering the Pleiotropic Role of ARID1a and RIF1 in Endometrioid Ovarian Cancer. (PubMed, Cells)

In conclusion, our study offers a new perspective, emphasizing that EOC is a distinct clinical and molecular entity. We demonstrated the expression patterns of ARID1a/BAF250a and RIF1 in EOC, establishing their potential relevance in the context of tumor biology and malignant transformation.

8 days ago

Journal • BRCA Biomarker

BRCA1 (Breast cancer 1, early onset) • ARID1A (AT-rich interaction domain 1A) • RIF1 (Replication Timing Regulatory Factor 1)

BRCA1 mutation • ARID1A mutation

Morphologic, immunohistochemical, and preliminary molecular findings of primary ovarian carcinoid tumors in a tertiary center cohort. (PubMed, Pathol Res Pract)

A likely pathogenic ARID1A p.Q1494* variant was identified in one mixed-architecture POCT with insular and trabecular components, lymphovascular invasion, and a relatively higher Ki-67 index in the insular component; however, this isolated finding should be interpreted as exploratory and requires validation in larger cohorts. To our knowledge, this likely pathogenic ARID1A variant is sporadically identified in one POCT case for the first time in published literature, warranting further investigation.

9 days ago

Journal

ARID1A (AT-rich interaction domain 1A) • NKX2-1 (NK2 Homeobox 1) • CDX2 (Caudal Type Homeobox 2) • SYP (Synaptophysin)

ARID1A mutation

11d

Comprehensive Genomic Characterization Between Urothelial Carcinoma Subtypes/Divergent Differentiation (S/DD) and Pure Urothelial Carcinoma Using a Large-Scale Japanese Genomic Panel Dataset. (PubMed, Int J Urol)

Using a large-scale Japanese genomic panel dataset, we characterized the molecular alterations associated with S/DD. S/DD frequently exhibits low Nectin-4 expression and basal-like molecular features, which may have implications for treatment selection and inform future therapeutic strategies.

11 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • FGFR3 (Fibroblast growth factor receptor 3) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • ARID1A (AT-rich interaction domain 1A) • CCND1 (Cyclin D1) • FGF19 (Fibroblast growth factor 19) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • KDM6A (Lysine Demethylase 6A) • FGF4 (Fibroblast growth factor 4) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • GATA3 (GATA binding protein 3) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)

PD-L1 expression • TP53 mutation • EGFR expression • ARID1A mutation • FGFR3 mutation • RB1 mutation

11d

Comparative analysis of genomic profiles and clinical outcomes in cholangiocarcinoma and gallbladder cancer. (PubMed, Sci Rep)

In the MSKCC cohort, high tumor mutational burden (TMB-Hmed) correlated with poorer OS (HR = 1.43, P = 0.01), while PBRM1 mutations were associated with improved survival (HR = 0.50, P = 0.02). This study underscores the distinct genomic profiles of GBC and CCA, offering valuable insights into the molecular underpinnings of these aggressive cancers and supporting the development of precision medicine strategies.

11 days ago

Clinical data • Journal • Tumor mutational burden

KRAS (KRAS proto-oncogene GTPase) • TMB (Tumor Mutational Burden) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • CCNE1 (Cyclin E1) • MCL1 (Myeloid cell leukemia 1) • PBRM1 (Polybromo 1) • ARID2 (AT-Rich Interaction Domain 2) • SOX2

TMB-H • ARID1A mutation

14d

Differential DNA damage response to WRN inhibition identifies a targetable vulnerability in ARID1A-mutated cancers. (PubMed, Sci Adv)

The antitumor efficacy of WRN inhibition alone and in combination with p21 inhibition was validated using cell line-based xenograft and patient-derived xenograft mouse models. Our findings define WRN as a selective therapeutic target in ARID1A-mutated cancers and suggest a combinatorial strategy of WRN and p21 inhibition as a therapeutic approach.

14 days ago

Journal

ARID1A (AT-rich interaction domain 1A) • CHEK2 (Checkpoint kinase 2) • CHEK1 (Checkpoint kinase 1) • WRN (WRN RecQ Like Helicase) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)

ARID1A mutation

17d

In silico analysis of driver genes in squamous cell carcinoma of the cervix: insights into their biological functions, prognosis, immune infiltration, and therapy. (PubMed, World J Surg Oncol)

Collectively, our analysis describes the driver genes and mutation characteristics in SCC. The multi-cohort and network-based framework employed in this study identifies candidate hub genes that warrant further clinical investigation in cervical cancer.

17 days ago

Journal

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • STK11 (Serine/threonine kinase 11) • ARID1A (AT-rich interaction domain 1A) • NOTCH1 (Notch 1) • KMT2D (Lysine Methyltransferase 2D) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • KMT2C (Lysine Methyltransferase 2C) • FAT1 (FAT atypical cadherin 1) • EP300 (E1A binding protein p300) • CASP8 (Caspase 8)

TP53 mutation • KRAS mutation • PIK3CA mutation • ARID1A mutation • STK11 mutation

Herceptin (trastuzumab) • everolimus • Piqray (alpelisib)

17d

ARID1A loss drives gastric signet ring cell carcinoma by regulating mucin production and secretion. (PubMed, Nat Commun)

Inhibition of Brd9 ameliorates the malignancy of SRCC. Thus, our study reveals dual roles of ARID1A in both mucin production and secretion, providing new mechanistic insights and potential therapeutic vulnerabilities in SRCC.

17 days ago

Journal

TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A)

TP53 mutation • ARID1A mutation

18d

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors (clinicaltrials.gov)

P1, N=54, Recruiting, M.D. Anderson Cancer Center | Trial completion date: May 2026 --> Jun 2028 | Trial primary completion date: May 2026 --> Mar 2028

18 days ago

Trial completion date • Trial primary completion date

PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • STK11 (Serine/threonine kinase 11) • ARID1A (AT-rich interaction domain 1A) • NF1 (Neurofibromin 1) • KEAP1 (Kelch Like ECH Associated Protein 1) • PD-1 (Programmed cell death 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)

PIK3CA mutation • PTEN mutation • ARID1A mutation • STK11 mutation • KEAP1 mutation • NFE2L2 mutation

Avastin (bevacizumab) • paclitaxel • Truqap (capivasertib) • IPN60090

18d

Radiogenomic analysis of muscle-invasive bladder cancer using CT-based texture analysis. (PubMed, Bladder Cancer)

Our study demonstrates that CT-derived radiomics features can capture biologically and clinically relevant information in muscle-invasive bladder cancer. These findings support the potential utility of radiomics as a noninvasive, scalable adjunct to genomic profiling in MIBC.

18 days ago

Journal • Tumor mutational burden

TMB (Tumor Mutational Burden) • FGFR3 (Fibroblast growth factor receptor 3) • ARID1A (AT-rich interaction domain 1A) • EP300 (E1A binding protein p300) • CASP3 (Caspase 3)

TMB-H • ARID1A mutation • FGFR3 mutation

18d

Genetic mutations in metastatic adenocarcinoma of unknown primary. (PubMed, Otolaryngol Pol)

GNAS and PIK3CA mutations were linked to favorable outcomes, while ARID1A and NOTCH1 alterations indicated poor prognosis in ACUP. These results highlight the prognostic significance of specific genomic alterations and support integrating CGP into the clinical management of ACUP.

18 days ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • NOTCH1 (Notch 1) • KMT2D (Lysine Methyltransferase 2D) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • NOTCH3 (Notch Receptor 3) • GNAS (GNAS Complex Locus)

PIK3CA mutation • ARID1A mutation

FoundationOne® CDx